Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties.
Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties.
复制标题
DOI：
10.1007/s40520-023-02438-3
复制
发表时间：
2023-08
影响因子：
4
通讯作者：
Bruyere, Olivier
中科院分区：
文献类型：
--
作者：
Beaudart, Charlotte;Reginster, Jean-Yves;Thiyagarajan, Jotheeswaran Amuthavalli;Bautmans, Ivan;Bauer, Juergen;Burlet, Nansa;Cesari, Matteo;Cherubini, Antonio;Cooper, Cyrus;Cruz-Jentoft, Alfonso J.;Dawson-Hughes, Bess;Fielding, Roger A.;Harvey, Nicholas C.;Landi, Francesco;Laslop, Andrea;Maggi, Stefania;Montero-Errasquin, Beatriz;Concepcion, Prieto Yerro Maria;Rolland, Yves;Rizzoli, Rene;Visser, Marjolein;Bruyere, Olivier
病人的观点现在被广泛认为是评估卫生干预措施的一个关键因素。因此，提供强调患有特定疾病的患者的生活经历的具体且经验证的患者报告的结果测量是非常重要的。在肌肉减少症领域，唯一经过验证的特定健康相关生活质量（HRQoL）工具是肌肉减少症生活质量问卷（SarQoL）。该自我管理HRQoL问卷于2015年开发，由55个项目组成，分为22个问题，目前已翻译成35种语言。对SarQoL进行的19项验证研究一致证实了SarQoL检测患有和不患有肌肉减少症的老年人之间HRQoL差异的能力，其可靠性和有效性。另外两项观察性研究也表明了它对变化的反应。进一步开发并验证了仅包括14项的简短SarQoL，以减少潜在的给药负担。仍然鼓励对SarQoL问卷的心理测量特性进行研究，因为尚未在干预性研究的背景下测量SarQoL变化的反应性，因为目前存在的前瞻性数据有限，并且仍然没有定义低HRQoL的截止评分。此外，SarQoL主要用于患有肌肉减少症的社区居住老年人，并将受益于在其他类型人群中进行研究。本综述旨在为研究人员、临床医生、监管机构、制药行业和其他利益相关者提供截至2023年1月发布的SarQoL问卷的全面证据的明确摘要。在线版本包含补充材料，可通过10.1007/s40520-023-02438-3获得。
Patient perspectives are now widely recognized as a key element in the evaluation of health interventions. Therefore, the provision of specific and validated Patient Reported Outcome Measures that emphasize the lived experience of patients suffering from specific diseases is very important. In the field of sarcopenia, the only validated specific health-related quality of life (HRQoL) instrument available is the Sarcopenia Quality of Life questionnaire (SarQoL). This self-administrated HRQoL questionnaire, developed in 2015, consists of 55 items arranged into 22 questions and has currently been translated into 35 languages. Nineteen validation studies performed on SarQoL have consensually confirmed the capacity of SarQoL to detect difference in HRQoL between older people with and without sarcopenia, its reliability and its validity. Two further observational studies have also indicated its responsiveness to change. A short form SarQoL, including only 14 items has further been developed and validated to reduce the potential burden of administration. Research on the psychometric properties of SarQoL questionnaire is still encouraged as the responsiveness to change of SarQoL has not yet been measured in the context of interventional studies, as limited prospective data currently exist and as there is still not cut-off score to define a low HRQoL. In addition, SarQoL has mainly been used in community-dwelling older individuals with sarcopenia and would benefit to be studied in other types of populations. This review aims to provide to researchers, clinicians, regulators, pharmaceutical industries and other stakeholders a clear summary of comprehensive evidence on the SarQoL questionnaire published up to January 2023Query. The online version contains supplementary material available at 10.1007/s40520-023-02438-3.
登录
查看更多内容
影响因子：
2.5
作者：
Kull, Mart;Kallikorm, Riina;Lember, Margus
通讯作者：
Lember, Margus
影响因子：
2.3
作者：
Go, Seon Won;Cha, Young Hwa;Park, Hye Soon
通讯作者：
Park, Hye Soon
影响因子：
3
作者：
Gasparik, Andrea;Gabriela, Mihai;Maria, Pascanu Ionela
通讯作者：
Maria, Pascanu Ionela
影响因子：
8.9
作者：
Beaudart, Charlotte;Biver, Emmanuel;Bruyere, Olivier
通讯作者：
Bruyere, Olivier
影响因子：
3.6
作者：
Dzhus, Marta;Dzhus, Maria;Beaudart, Charlotte
通讯作者：
Beaudart, Charlotte